Form 4: Director Nicholas J. Valeriani Receives EW Stock Grant

Edwards Lifesciences Director Nicholas J. Valeriani was granted 5,127 restricted stock units as part of the company's nonemployee director incentive program.

Summary

• Director Nicholas J. Valeriani acquired 5,127 restricted stock units (RSUs) of Edwards Lifesciences Corporation common stock.
• The transaction occurred on May 8, 2026.
• The shares were granted at a price of $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program.
• Following this transaction, the director's total beneficial ownership is 84,423 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the passage of time or the occurrence of the next annual meeting of stockholders.

Future Outlook

The RSUs are scheduled to vest 100% after the earlier of one year from the grant date or the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation practices for independent directors at large-cap medical technology firms like Medtronic or Boston Scientific.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 5,127 RSUs in one year or at the next annual meeting of stockholders.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units